memori
federica
novelli
deriv
antiinfluenza
b
virus
activ
antirsv
activ
host
human
dhfr
inhibit
b
r
c
identifi
seri
structur
relat
antimalari
drug
cycloguanil
new
inhibitor
influenza
b
viru
respiratori
syncyti
viru
rsv
via
target
host
dihydrofol
reductas
dhfr
enzym
analogu
prove
activ
influenza
b
viru
low
micromolar
rang
best
compound
even
reach
submicromolar
potenc
zanamivir
ec
mm
markedli
exceed
time
antivir
efficaci
ribavirin
activ
also
observ
two
influenza
strain
includ
viru
mutant
form
proton
channel
preval
resist
mutat
amantadin
importantli
compound
display
nanomolar
activ
rsv
superior
select
index
sinc
ratio
cytotox
antivir
concentr
three
activ
compound
ec
mm
far
surpass
potenc
safeti
profil
licens
drug
ribavirin
ec
mm
si
orthoand
paramyxovirida
famili
compris
import
respiratori
pathogen
ie
influenza
b
virus
respiratori
syncyti
viru
rsv
respect
acut
respiratori
ill
caus
virus
repres
major
medic
problem
given
signific
morbid
potenti
mortal
particularli
vulner
popul
small
infant
elderli
peopl
patient
underli
medic
condit
besid
threat
new
influenza
viru
pandem
reason
global
constant
concern
sinc
current
arsen
antivir
drug
treat
prevent
influenza
rsv
infect
quit
limit
new
therapeut
highli
need
accord
recommend
world
health
organ
attent
given
innov
agent
broad
activ
divers
respiratori
virus
virus
oblig
intracellular
parasit
encod
multipl
virusspecif
protein
essenti
replic
also
depend
critic
interact
host
cell
protein
approv
antivir
drug
target
uniqu
protein
encod
one
viru
rang
close
relat
virus
strategi
prone
select
drugresist
particularli
virus
possess
high
mutabl
influenza
viru
requir
longterm
therapi
altern
relev
approach
address
host
factor
involv
viral
life
cycl
type
inhibitor
anticip
possess
markedli
higher
barrier
select
drugresist
virus
furthermor
may
display
broadspectrum
antivir
activ
deal
cellular
target
recruit
differ
virus
two
hostdirect
antivir
drug
maraviroc
receptor
antagonist
approv
hiv
therapi
alisporivir
cyclophylin
inhibitor
undergo
phase
iii
test
hepat
c
treatment
specif
host
protein
proven
critic
replic
divers
unrel
virus
yet
array
possibl
cellular
target
virushost
interactom
continu
grow
recent
review
influenza
rsv
first
exampl
broadlyact
antivir
drug
ribavirin
nucleosid
analogu
propos
act
directli
level
viral
polymeras
although
indirect
effect
via
inhibit
hostcel
imp
dehydrogenas
deplet
gtp
pool
seem
plausibl
anoth
enzym
purin
pyrimidin
pathway
dihydrofol
reductas
dhfr
catalyz
reduct
dihydrofol
dhf
tetrahydrofol
thf
crucial
cofactor
biosynthesi
imp
thymidyl
folat
antagonist
interf
dhfr
appli
divers
pharmacolog
ie
antimalari
antibacteri
antineoplast
set
licens
antifol
trimethoprim
pyrimethamin
cycloguanil
potent
inhibitor
bacteri
protozo
dhfr
respect
weak
inhibitor
mammalian
dhfr
enzym
hand
drug
methotrex
mtx
potent
unselect
dhfr
inhibitor
ki
nm
close
structur
similar
dihydrofol
acid
natur
substrat
enzym
mtx
show
bind
affin
human
dhfr
hdhfr
higher
folic
acid
explain
clinic
applic
anticanc
antiinflammatori
immunosuppress
agent
inde
mtx
capabl
affect
differ
intracellular
pathway
recent
describ
highlight
rather
complex
mechan
action
besid
import
therapeut
activ
relat
hdhfr
inhibit
ongo
research
effort
develop
novel
antifol
cancer
chemotherapi
microbi
infect
continu
extens
review
cycloguanil
activ
metabolit
antimalari
drug
proguanil
paludrin
malaron
approv
prophylaxi
treatment
infect
plasmodium
vivax
falciparum
speciesselect
activ
cycloguanil
pyrimethamin
tradit
attribut
higher
affin
drug
plasmodium
bifunct
dihydrofol
reductasethymidyl
synthetas
dhfrt
hdhfr
sinc
cycloguanil
relat
studi
aim
treat
pneumocysti
carinii
pneumonia
search
select
inhibitor
p
carinii
dhfr
host
dhfr
especi
human
enzym
inde
trimethoprim
antifol
wide
use
kind
infect
poor
inhibitor
p
carinii
dhfr
ki
mm
show
greater
select
hdhfr
ki
mm
exhibit
select
p
carinii
dhfr
inhibit
cycloguanil
relat
analogu
two
correspond
compound
disclos
bind
slightli
stronger
hdhfr
cycloguanil
ki
mm
p
carinii
enzym
cycloguanil
ki
mm
final
author
suggest
expect
select
fungal
enzym
inhibitor
even
compound
higher
speciesselect
profil
hdhfr
show
improv
agent
current
use
treat
p
carinii
infect
previou
studi
focus
design
antivir
agent
explor
divers
origin
chemotyp
search
novel
promis
deriv
manuscript
report
first
time
intrigu
antivir
profil
cycloguanil
base
inform
deem
interest
proceed
work
direct
design
synthesi
evalu
antivir
activ
cytotox
play
compound
wide
rang
rna
dna
virus
particular
explor
relev
structureact
relationship
sar
exhibit
within
seri
structur
analogu
cycloguanil
includ
number
compound
prove
inhibit
viru
reproduct
target
host
cell
dhfr
particular
new
class
hostdirect
antivir
agent
display
promis
dual
activ
influenza
respiratori
syncyti
viru
rsv
select
compound
also
test
hdhfr
order
gain
knowledg
efficaci
versu
recombin
protein
final
dock
studi
perform
order
support
disclos
probabl
bind
mode
deriv
hdhfr
ligand
foster
lead
optim
process
compound
object
present
studi
character
scaffold
cite
cycloguanil
identifi
us
prototyp
new
class
antivir
agent
exploit
host
dhfr
inhibit
mechan
order
better
clarifi
intrigu
effect
tune
adequ
host
dhfr
inhibit
develop
antivir
compound
endow
optim
antivir
activ
safeti
profil
proceed
design
synthesi
evalu
seri
cycloguanil
analogu
furthermor
sever
studi
compound
contain
pyridopyrimidin
system
bioisoster
triazin
core
hdhfrtarget
deriv
prompt
us
deepen
sar
requir
within
seri
congen
fig
thu
differ
function
design
fig
explor
effect
biolog
activ
result
chemic
variat
paracl
substitu
r
phenyl
ring
andor
two
methyl
group
r
r
c
cycloguanil
smaller
bulkier
alkyl
group
five
compound
newli
synthes
other
resynthes
test
new
antivir
agent
capabl
inhibit
host
cell
dhfr
also
includ
investig
cycloguanil
isomer
anilinodihydrotriazin
proguanil
metabol
precursor
cycloguanil
biguanid
second
major
metabolit
proguanil
two
planar
analogu
pyrimethamin
trimethoprim
potent
inhibitor
protozo
bacteri
dhfr
respect
compound
underw
cell
cultur
evalu
cytotox
antivir
activ
wide
rang
rna
dna
virus
aim
determin
host
dhfr
target
compound
seri
along
viru
replic
pathway
promis
compound
test
recombin
protein
hdhfr
enzym
success
dock
studi
allow
find
molecular
rational
mechan
compound
could
inhibit
hdhfr
deem
interest
synthes
evalu
antivir
activ
seri
bear
posit
aromat
ring
various
substitut
posit
one
two
alkyl
aromat
moieti
fig
test
dihydrotriazin
alreadi
describ
reprepar
accord
cite
refer
synthes
compound
achiev
onestep
acidcatalyz
cyclocondens
among
aromat
amin
dicyandiamid
carbonyl
compound
synthes
use
twocompon
synthes
progress
two
step
condens
preform
arylbiguanid
carbonyl
deriv
progress
reaction
monitor
mean
neg
result
color
copper
complex
form
characterist
biguanid
freshli
cuprammonium
sulphat
solut
treatment
cycloguanil
hydrochlorid
excess
alkali
reflux
undergo
intramolecular
rearrang
isomer
anilinodihydrotriazin
compound
compound
known
free
base
synthet
rout
crystal
directli
reaction
mixtur
pure
hydrochlorid
aforement
three
compon
synthesi
thu
experiment
describ
togeth
novel
compound
scheme
new
compound
show
excel
analyt
spectroscop
data
good
agreement
structur
see
experiment
part
h
nmr
spectra
proton
nitrogen
nucleu
give
rise
net
singlet
near
amino
group
yield
signal
rang
antivir
activ
compound
influenza
subtyp
b
virus
present
tabl
procedur
use
exponenti
grow
mdck
cell
virusinduc
cytopath
effect
cpe
monitor
either
microscopi
cell
viabil
test
shown
tabl
overal
correl
antivir
ec
valu
obtain
either
method
indic
reliabl
observ
antivir
effect
hand
microscop
evalu
reveal
sever
compound
produc
cytostat
effect
yield
minimum
cytotox
concentr
mcc
instanc
mm
cycloguanil
comparison
cc
valu
cell
viabil
assay
mm
indic
true
cytotox
effect
manifest
cell
kill
seen
higher
concentr
worth
note
cycloguanil
activ
metabolit
prodrug
proguanil
antimalari
drug
consid
safe
even
use
pregnanc
furthermor
compound
cytotox
mdck
cell
leav
unaffect
mcc
mm
human
hela
tabl
primat
vero
cell
line
tabl
use
grow
virus
investig
addit
select
compound
assay
cytotox
human
airway
epitheli
cell
confirm
mcc
valu
higher
mm
data
shown
tabl
reveal
follow
trend
twentyfour
thirtythre
compound
prove
activ
least
one
influenza
viru
strain
display
activ
three
influenza
viru
strain
cycloguanil
prototyp
class
deriv
exhibit
modest
activ
influenza
virus
potent
influenza
b
viru
ec
mm
base
interest
observ
studi
orient
toward
design
synthesi
effect
agent
firstli
replac
chlorin
atom
posit
aromat
ring
explor
introduct
either
electronwithdraw
group
isoster
chlorin
f
br
electrondonor
group
ch
och
permit
without
chang
activ
wherea
polar
electronwithdraw
group
cooh
cooet
detriment
assum
chlorin
wellsuit
substitu
investig
influenc
monosubstitut
cycloguanilrel
isom
disubstitut
deriv
compound
bear
lipophil
electronwithdraw
group
posit
aromat
ring
prove
strong
inhibitor
submicromolar
potenc
influenza
b
viru
ec
mm
respect
lower
activ
influenza
virus
contrast
compound
poorli
activ
influenza
b
ec
mm
substitut
abolish
activ
sinc
data
clearli
indic
lipophil
electronwithdraw
atom
posit
properli
modul
antivir
activ
next
synthes
analogu
compound
show
activ
profil
compar
wherea
bromin
deriv
found
best
influenza
b
inhibitor
among
entir
seri
ec
mm
next
step
vari
two
methyl
group
c
scaffold
introduc
bulkier
alkyl
group
two
one
deriv
aceton
achiev
perform
condens
methyl
ethyl
keton
methyl
isopropyl
keton
cyclopentanon
cyclohexanon
progress
increas
substitu
size
led
proport
decreas
activ
influenza
viru
much
less
impact
influenza
b
even
combin
substitut
among
three
compound
monosubstitut
posit
c
ch
group
ec
mm
toler
keep
influenza
b
inhibit
whilst
npropyl
chain
phenyl
ring
detriment
sinc
vivo
applic
cycloguanil
prodrug
proguanil
check
whether
also
prodrug
biguanid
possess
antiinfluenza
activ
two
main
metabolit
antimalari
drug
proguanil
activ
form
cycloguanil
inact
biguanid
constitut
respect
total
drug
concentr
plasma
compound
shown
inact
alik
anilinedihydrotriazin
isom
cycloguanil
trimethoprim
pyrimethamin
chosen
fulli
unsatur
cycloguanil
analogu
pyrimethamin
influenza
b
viru
appear
sensit
reduct
thf
pool
could
point
higher
sensit
influenza
b
viru
nucleotid
imbal
perhap
relat
slower
growth
kinet
influenza
b
compar
influenza
viru
although
seem
contradict
find
gtpdeplet
agent
ribavirin
display
similar
ec
valu
influenza
b
virus
tabl
recent
balgi
et
al
use
highthroughput
yeast
growth
restor
assay
screen
compound
identifi
three
tetrahydrotriazin
antivir
activ
plaqu
reduct
assay
one
except
efficaci
assess
mm
wild
type
proton
channel
twoelectrod
voltag
clamp
tevc
assay
base
chemic
resembl
deem
interest
assess
also
abl
inhibit
proton
channel
express
xenopu
oocyt
use
tevc
assay
mm
neither
three
compound
significantli
inhibit
wild
type
mutant
channel
thu
exclud
inhibit
antivir
mechan
action
virusinfect
mdck
cell
data
shown
sever
compound
produc
promis
antivir
effect
similar
cpe
reduct
assay
rsv
hela
cell
tabl
sinc
compound
cytotox
mm
highest
concentr
test
select
index
ie
ratio
mcc
ec
calcul
least
activ
analogu
compound
inhibit
rsv
replic
nanomolar
concentr
far
surpass
antivir
activ
ribavirin
ec
mm
si
latter
small
molecul
drug
treat
rsv
infect
consequ
limit
efficaci
need
prolong
aerosol
administr
risk
toxic
use
limit
children
high
risk
therefor
effect
safe
drug
strongli
need
treat
sever
rsvlink
respiratori
patholog
also
affect
adult
particularli
elderli
thu
highli
potent
compound
could
interest
lead
compound
chemic
derivat
develop
improv
rsv
inhibitor
similar
observ
influenza
viru
drug
cycloguanil
pyrimethamin
found
equipot
rsvinhibitor
ec
valu
mm
respect
nearli
one
order
magnitud
superior
valu
ribavirin
compound
activ
rsv
ie
also
inact
influenza
three
activ
rsv
inhibitor
ie
ec
mm
tabl
also
best
ec
valu
tabl
influenza
henc
clear
biochem
mechan
explain
inhibitori
effect
class
compound
toward
rsv
influenza
viru
rna
virus
test
either
hela
tabl
vero
cell
tabl
also
inhibit
member
rotavirida
found
activ
low
micromolar
rang
without
visibl
cytotox
mcc
mm
compound
exhibit
broader
antivir
activ
concentr
quit
close
produc
cytotox
mcc
mm
tabl
neither
compound
inhibit
replic
yellow
fever
viru
tabl
member
flavivirida
describ
anoth
report
sensit
methotrex
prototyp
inhibitor
mammalian
dhfr
enzym
final
evalu
human
embryon
lung
hel
fibroblast
cell
sever
dna
virus
herp
adenoor
poxviru
famili
plu
coronaviru
rna
viru
neither
compound
prove
activ
virus
data
shown
sinc
host
cell
dhfr
inhibit
seem
plausibl
explan
observ
antivir
effect
perform
combin
experi
rsvinfect
hela
cell
expos
compound
combin
differ
concentr
natur
dhfr
substrat
dihydrofol
acid
reaction
much
higher
impact
viru
replic
cell
growth
concur
promis
antivir
select
hostdirect
dhfr
inhibitor
final
assay
select
compound
hdhfr
order
confirm
observ
antivir
activ
rsv
clearli
influenc
enzym
inhibit
concern
inhibit
experiment
data
test
compound
hdhfr
tabl
sar
move
trend
compar
antivir
activ
cellbas
assay
ki
valu
rang
mm
best
antivir
compound
decreas
order
bulkier
spirocompound
less
effect
ki
valu
equal
mm
cycloguanil
pyrimethamin
display
degre
potenc
lower
potent
compound
interestingli
almost
compound
test
similar
trend
observ
ki
hdhfr
antivir
activ
influenza
b
viru
respiratori
syncyti
viru
thu
support
concept
observ
antivir
effect
sustain
also
hdhfr
inhibit
fig
moreov
kinet
inhibit
studi
cycloguanil
perform
competit
inhibit
pattern
observ
toward
substrat
bind
human
enzym
fig
thu
deriv
prove
effici
work
weaken
viru
replic
machineri
direct
inhibitori
effect
versu
host
human
dhfr
molecular
model
studi
perform
hdhfr
inhibitor
identifi
explor
structur
basi
interact
mention
compound
human
enzym
dock
studi
perform
use
xray
crystallograph
structur
hdhfr
complex
pyridopyrimidinebas
inhibitor
pdb
code
resolut
human
dhfr
inhibitor
compound
consid
posit
control
fig
main
issu
address
clarifi
dock
studi
role
play
nucleu
hydrophob
framework
includ
phenyl
ring
substitu
respect
core
phenylsubstitut
moieti
addit
pyrimethamin
also
submit
dock
calcul
shown
similar
antivir
behaviour
cycloguanil
shown
fig
engag
hbond
two
nh
substitu
place
onto
pyrimidin
core
carbonyl
group
sidechain
respect
whole
planar
bicycl
ring
involv
stack
isopropyl
phenyl
ring
project
toward
display
van
der
waal
contact
consequ
kind
contact
effici
stabil
within
hdhfr
bind
site
lead
complex
favour
valu
estim
bind
affin
hdhfri
dg
kj
mol
harmoni
high
compound
potenc
profil
ki
nm
tabl
base
dock
calcul
tabl
small
bulki
alkyl
group
chosen
presenc
meta
substitu
place
rather
ortho
para
posit
phenyl
ring
prove
prefer
accordingli
cycloguanil
character
weak
hbond
ring
move
toward
opposit
side
caviti
occupi
isopropyl
phenyl
ring
refer
inhibitor
fig
compar
dock
mode
observ
pyrimethamin
shown
tabl
relat
complex
display
quit
adequ
compar
valu
predict
bind
affin
energi
dg
kjmol
interestingli
promis
deriv
share
common
dock
mode
exhibit
requir
hbond
mean
two
nh
group
scaffold
shown
compound
fig
addit
dimethyl
substitut
also
presenc
ring
prove
particularli
effect
properli
mimic
posit
display
within
xray
crystallograph
structur
hdhfr
consequ
effici
character
import
crucial
bond
biolog
target
previous
discuss
compound
therefor
experienc
favour
predict
bind
affin
profil
agreement
experiment
data
particular
compound
dg
kjmol
prove
promis
ki
mm
convers
presenc
bulki
group
introduct
cycloalkyl
ring
move
deriv
toward
quit
turn
dock
mode
compar
shown
compound
fig
inde
one
two
nh
group
onto
dihydrotriazin
ring
abl
mimic
role
play
detect
one
hbond
addit
bioisoster
replac
pyridopyrimidin
scaffold
smaller
dihydrotriazin
one
inevit
impair
abil
compound
display
pattern
hydrophob
contact
previous
mention
compound
one
seri
propos
exhibit
kind
dock
mode
lose
keycontact
one
hbond
sever
van
basi
expect
nucleu
properli
decor
small
rigid
planar
group
could
repres
interest
scaffold
abl
fulfil
minim
pharmacophor
requir
exert
hdhfr
inhibit
report
describ
discoveri
new
class
hostdirect
antivir
agent
character
scaffold
respons
host
human
dhfr
inhibit
mechan
hosttarget
antivir
repres
altern
emerg
strategi
address
host
factor
involv
viru
life
cycl
type
inhibitor
could
show
markedli
higher
barrier
select
drugresist
virus
furthermor
display
broadspectrum
antivir
activ
interact
common
cellular
target
recruit
differ
virus
interest
dual
activ
influenza
respiratori
syncyti
virus
via
inhibit
cellular
human
dhfr
enzym
point
host
factor
new
therapeut
target
two
respiratori
virus
fact
revers
effect
antivir
activ
demonstr
rsvinfect
hela
cell
expos
compound
combin
differ
concentr
dihydrofol
acid
natur
dhfr
substrat
promis
compound
test
recombin
protein
hdhfr
also
confirm
bind
enzym
submicromolar
rang
kinet
inhibit
studi
cycloguanil
show
competit
inhibit
behavior
dock
studi
disclos
probabl
bind
mode
class
compound
hdhfr
ligand
notabl
antivir
activ
rsv
influenza
b
virus
cellbas
assay
ki
valu
recombin
hdhfr
enzym
also
estim
bind
affin
dg
share
interest
compar
sar
trend
possibl
suppress
influenza
viru
interf
purin
pyrimidin
pathway
propos
enzym
studi
first
identifi
relev
host
human
dhfr
antivir
therapi
compound
prove
effect
inhibitor
influenza
b
viru
give
submicromolar
activ
case
potent
analogu
compar
favor
licens
antivir
drug
zanamivir
even
exceed
antivir
efficaci
ribavirin
compound
also
possess
low
micromolar
activ
influenza
viru
even
importantli
nanomolar
activ
rsv
select
index
least
far
surpass
antivir
activ
refer
drug
ribavirin
novel
hostdirect
deriv
combin
promis
antivir
activ
low
cost
easili
access
chemic
synthesi
therefor
result
provid
foundat
explor
structureact
relationship
class
compound
versu
dhfr
especi
human
enzym
appar
import
role
host
enzym
influenza
rsv
viru
replic
gener
method
synthesi
deriv
solut
substitut
anilin
hydrochlorid
mmol
ml
aceton
ml
meoh
react
rt
dicyandiamid
mmol
equiv
stir
h
compound
separ
directli
reaction
mixtur
thu
collect
filtrat
wash
aceton
recrystal
solvent
case
compound
solut
evapor
dryness
vacuum
residu
recrystal
meoh
compound
antivir
activ
cell
cultur
determin
broad
panel
virus
use
cytopath
effect
cpe
reduct
assay
describ
detail
elsewher
human
influenza
b
virus
examin
madindarbi
canin
kidney
mdck
cell
human
cervix
carcinoma
hela
cell
use
studi
respiratori
syncyti
viru
rsv
strain
long
vesicular
stomat
viru
vsv
coxsacki
viru
african
green
monkey
vero
cell
use
viru
sindbi
viru
coxsacki
viru
punta
toro
viru
yellow
fever
viru
follow
virus
investig
human
embryon
lung
fibroblast
cell
herp
simplex
viru
type
vaccinia
viru
human
adenoviru
type
vsv
human
coronaviru
final
activ
human
immunodefici
viru
type
assess
human
lymphoblast
cell
semiconflu
cell
cultur
plate
infect
viru
multipl
infect
ccid
cell
cultur
infect
dose
pfu
plaqu
form
unit
per
well
simultan
viru
serial
dilut
test
refer
compound
ad
plate
incub
c
c
case
influenza
coronaviru
clear
cpe
appar
ie
day
day
case
microscopi
perform
score
cpe
determin
antivir
activ
express
effect
concentr
ec
cytotox
express
minimum
cytotox
concentr
mcc
case
influenza
viru
hiv
virusinduc
cpe
also
monitor
colorimetr
formazanbas
cell
viabil
assay
capabl
synthes
chemic
librari
inhibit
hdhfr
protein
evalu
spectrophotometr
assay
perform
dhf
substrat
dihydrofol
timeread
enzymat
consumpt
nm
inhibitor
compound
dissolv
dmso
order
initi
concentr
equal
mm
first
inhibit
assay
one
concentr
point
mm
perform
order
determin
best
concentr
rang
calcul
ic
valu
inhibit
assay
perform
consid
final
volum
equal
ml
detail
sever
reagent
ad
follow
order
ddw
hdhfr
enzym
concentr
mm
inhibitor
compound
singl
evalu
concentr
dhf
substrat
concentr
mm
te
buffer
end
nadph
ad
reaction
mixtur
concentr
valu
equal
mm
start
kinet
enzym
reaction
base
obtain
inhibit
data
concentr
rang
ic
evalu
select
inhibitor
compound
assay
five
concentr
valu
equal
mm
except
compound
assay
mm
base
result
inhibit
data
ic
valu
compound
michaelismenten
kinet
steadyst
condit
calcul
compound
built
parameter
gasteigerhuckel
method
energi
minim
within
moe
use
forcefield
ligand
use
proton
state
dock
calcul
within
xray
structur
human
dhfr
pdb
code
perform
use
leadit
softwar
suit
wwwbiosolveitcom
includ
flexx
score
algorithm
base
calcul
bind
free
energi
mean
gibbshelmholtz
equat
softwar
detect
bind
site
defin
radiu
far
cocrystal
ligand
order
set
spheric
search
space
dock
approach
standard
set
dock
strategi
follow
choos
socal
hybrid
approach
enthalpi
entropi
criteria
relat
score
function
evalu
describ
literatur
deriv
dock
pose
priorit
score
valu
lowest
energi
pose
compound
dock
protein
structur
ligand
refin
rescor
assess
algorithm
hyde
includ
leadit
softwar
hyde
modul
consid
dehydr
enthalpi
hydrogen
bond
final
reliabl
select
dock
pose
assess
use
ps
run
molecular
dynam
md
constant
temperatur
follow
allatom
energi
minim
lowmodemd
implement
moe
softwar
kind
modul
allow
perform
exhaust
conform
analysi
ligandreceptor
bind
site
complex
previous
discuss
case
studi
